Osteopontin in pancreatic cancer: A systematic review.

Med Int (Lond) · 2026 · PMC13040131 · PMID 41928921

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Its low-dose administration did not lead to improved kidney function, but it showed a trend toward upregulation of osteopontin, accompanied by increased renal macrophage-infiltration, and enhanced parenchymal TGF-β1 and IL-10.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.